European Journal of Chemistry

QSAR rationales for the 1,2-diarylcyclopentenes as prostaglandin EP1 receptor antagonists: Potentially useful in the treatment of inflammatory pain

Article Sidebar

PDF
Published: Dec 22, 2010
DOI: https://doi.org/10.5155/eurjchem.1.4.325-334.195
Keywords:
1, 2-Diarylcyclopentenes, EP1 receptor antagonists, Dragon descriptors, QSAR, CP-MLR, Partial least square analysis
Section
Research Article
Issue
Vol. 1 No. 4 (2010): December 2010
Dates
Received 2010-07-06
Accepted 2010-09-01
Published 2010-12-22


Main Article Content

Brij Kishore Sharma
Department of Chemistry, Shri Kalyan Government College, Sikar, IN-332001, India
Pradeep Pilania
Department of Chemistry, Shri Kalyan Government College, Sikar, IN-332001, India
Prithvi Singh
Department of Chemistry, Shri Kalyan Government College, Sikar, IN-332001, India

Abstract

The EP1 receptor inhibitory activity of 1,2-diarylcyclopentene derivatives have been quantitatively analyzed in terms of Dragon descriptors. The derived QSAR models have provided rationales to explain the EP1 receptor inhibitory activity of 1,2-diarylcyclopentene derivatives. The 2D-autocorrelation descriptors (MATS4e, MATS5e, MATS7v, GATS5e and GATS7v) have highlighted the role of atomic properties in respective lags of autocorrelations to explain the biological actions of 1,2-diarylcyclopentene analogues. Presence of fluorine atom (nF) and smaller distance between N and O atoms (T(N..O)) in molecular structures, in addition to Kier-Hall electrotopological states (Ss) have also shown prevalence to optimize the EP1 receptor inhibitory activity. Partial least square analysis has confirmed the dominance of information content of the combinatorial protocol in multiple linear regression identified descriptors. Applicability domain analysis revealed that the suggested model matches the high quality parameters with good fitting power and capability of assessing external data. All the compounds are within the applicability domain of the proposed model and were evaluated correctly.

1_4_325_334_800


icon graph This Abstract was viewed 1366 times | icon graph Article PDF downloaded 826 times

How to Cite
(1)
Sharma, B. K.; Pilania, P.; Singh, P. QSAR Rationales for the 1,2-Diarylcyclopentenes As Prostaglandin EP1 Receptor Antagonists: Potentially Useful in the Treatment of Inflammatory Pain. Eur. J. Chem. 2010, 1, 325-334.

Article Details

Share
Links for Article


Crossref - Scopus - Google - European PMC
Crossref
Scopus
Google Scholar
Europe PMC
References

[1]. Murakami, M.; Nakatani, Y.; Tanioka, T.; Kudo, I. Prostaglandins Other Lipid Mediat. 2002, 68-69, 383-399.
doi:10.1016/S0090-6980(02)00043-6

[2]. Claveau, D.; Sirinyan, M.; Guay, J.; Gordon, R.; Chan, C-C.; Bureau, Y.; Riendeau, D.; Mancini, J. A. J. Immunol. 2003, 170, 4738-4744.

[3]. Trebino, C. E.; Stock, J. L.; Gibbons, C. P.; Naiman, B. M.; Wachtmann, T. S.; Umland, J. P.; Pandher, K.; Lapointe, J-M.; Saha, S.; Roach, M. L.; Carter, D.; Thomas, N. A.; Durtschi, B. A.; McNeish, J. D.; Hambor, J. E.; Jakobsson, P-J.; Carty, T. J.; Perez J. R.; Audoly, L. P. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 9044-9049.
doi:10.1073/pnas.1332766100
PMid:12835414    PMCid:166435

[4]. Kamei, D.; Yamakawa, K.; Takegoshi, Y.; Mikami-Nakanishi, M.; Nakatani, Y.; Oh-ishi, S.; Yasui, H.; Azuma, Y.; Hirasawa, N.; Ohuchi, K.; Kawaguchi, H.; Ishikawa, Y.; Ishii, T.; Uematsu, S.; Akira, S.; Murakami, M.; Kudo, I. J. Biol. Chem. 2004, 279, 33684-33695.
doi:10.1074/jbc.M400199200
PMid:15140897

[5]. Mabuchi, T.; Kojima, H.; Abe, T.; Takagi, K.; Sakurai, M.; Ohmiya, Y.; Uematsu, S.; Akira, S.; Watanabe, K.; Ito, S. Neuroreport 2004, 15, 1395-1398.
doi:10.1097/01.wnr.0000129372.89000.31
PMid:15194860

[6]. Camu, F.; Shi, L.; Vanlersberghe, C. Drugs 2003, 63(suppl. 1), 1-7.
doi:10.2165/00003495-200363001-00002
PMid:14506906

[7]. Bianchi, M.; Broggini, M. Drugs 2003, 63(suppl. 1), 37-46.
doi:10.2165/00003495-200363001-00006
PMid:14506910

[8]. Jeger, R. V.; Greenberg, J. D.; Ramanathan, K.; Farkouh, M. E. Exp. Rev. Clin. Immunol. 2005, 1, 37-45.
doi:10.1586/1744666X.1.1.37
PMid:20477653

[9]. Lee, Y.; Rodriguez, C.; Dionne, R. A. Curr. Pharm. Des. 2005, 11, 1737-1755.
doi:10.2174/1381612053764896
PMid:15892672

[10]. Akarca, U. S. Curr. Pharm. Des. 2005, 11, 1779-1793.
doi:10.2174/1381612053764904
PMid:15892675

[11]. Sheen, C. L.; MacDonald, T. M. Exp. Opin. Pharmacother. 2002, 3, 265-269.
doi:10.1517/14656566.3.3.265
PMid:11866677

[12]. Hawkey, C. J.; Jackson, L.; Harper, S. E.; Simon, T. J.; Mortensen, E.; Lines, C. R. Aliment. Pharmacol. Ther. 2001, 15, 1-9.
doi:10.1046/j.1365-2036.2001.00894.x

[13]. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Bosi Ferraz, M.; Hawkey, C. J.; Hochberg, M. C.; Kvien T. K.; Schnitzer, T. J.; VIGOR study group. N. Eng. J. Med. 2000, 343, 1520-1528.
doi:10.1056/NEJM200011233432103
PMid:11087881

[14]. Silverstein, F. E.; Faich, G.; Goldstein, J. L.; Simon, L. S.; Pincus, T.; Whelton, A.; Makuch, R.; Eisen, G.; Agrawal, N. M.; Stenson, W. F.; Burr, A. M.; Zhao, W. W.; Kent, J. D.; Lefkowith, J. B.; Verburg, K. M.; Geis, G. S. J. Am. Med. Assoc. 2000, 284, 1247-1255.
doi:10.1001/jama.284.10.1247
PMid:10979111

[15]. Merck & Co. Press Release; 30 September 2004. http://www.merck.com.

[16]. Mukherjee, D.; Nissen, S. E.; Topol, E. J. J. Am. Med. Assoc. 2001, 286, 954-959.
doi:10.1001/jama.286.8.954
PMid:11509060

[17]. Mamdani, M.; Juurlink, D. N.; Lee, D. S.; Rochon, P. A.; Kopp, A.; Naglie, G.; Austin, P. C.; Laupacis, A.; Stukel, T. A. Lancet 2004, 363, 1751-1756.
doi:10.1016/S0140-6736(04)16299-5

[18]. Scheen, A. J. Rev. Med. Liege 2004, 59, 565-569.
PMid:15623076

[19]. Bresalier, R. S.; Sandier, R. S.; Quan, H.; Bolognese, J. A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M. A.; Baron, J. A. N. Engl. J. Med. 2005, 352, 1092-1102.
doi:10.1056/NEJMoa050493
PMid:15713943

[20]. Solomon, S. D.; McMurray, J. J. V.; Pfeffer, M. A.; Wittes, J.; Fowler, R.; Finn, P.; Anderson, W. F.; Zauber, A.; Hawk E.; Bertagnolli, M. N. Engl. J. Med. 2005, 352, 1071-1080.
doi:10.1056/NEJMoa050405
PMid:15713944

[21]. Fitzgerald, G. A. N. Engl. J. Med. 2004, 351, 1709-1711.
doi:10.1056/NEJMp048288
PMid:15470192

[22]. Lagakos, S. W. N. Engl. J. Med. 2006, 355, 113-117.
doi:10.1056/NEJMp068137
PMid:16801354

[23]. Meagher, E. A. Curr. Pharm. Des. 2004, 10, 603-611.
doi:10.2174/1381612043453153
PMid:14965323

[24]. Coleman, R. A.; Smith, W. L.; Narumiya, S. Pharmacol. Rev. 1994, 46, 205-229.
PMid:7938166

[25]. Breyer, R. M.; Bagdassarian, C. K.; Myers, S. A.; Breyer, M. D. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 661-690.
doi:10.1146/annurev.pharmtox.41.1.661
PMid:11264472

[26]. Narumiya, S.; Sugimoto, Y.; Ushikubi, F. Physiol. Rev. 1999, 79, 1193-1226.
PMid:10508233

[27]. Coleman, R. A.; Kennedy, I.; Humphrey, P. P. A.; Bunce, K.; Lumley, P. Comprehensive Medicinal Chemistry, 3rd volume, Pergamon: Oxford, UK, 1990.

[28]. Hata, A. N.; Breyer, R. M. Pharmacol. Ther. 2004, 103, 147-166.
doi:10.1016/j.pharmthera.2004.06.003

[29]. Ungrin, M. D.; Carrière, M-C.; Denis, D.; Lamontagne, S.; Sawyer, N.; Stocco, R.; Tremblay, N.; Metters, K. M.; Abramovitz, M. Mol. Pharmacol. 2001, 59, 1446–1455.
PMid:11353805

[30]. Hallinan, E.; Hagen, T.; Jusa, R.; Tsymbalov, S.; Rao, S.; van Hoeck, J-P.; Rafferty, M.; Stapelfeld, A.; Savage, M.; Reichman, M. J. Med. Chem. 1993, 36, 3293-3299.
doi:10.1021/jm00074a010
PMid:7901416

[31]. Hallinan, E.; Stapelfeld, A.; Savage, M.; Reichman, M. Bioorg. Med. Chem. Lett. 1994, 4, 509-514.
doi:10.1016/0960-894X(94)80027-8

[32]. Lanthorn, T.; Bianchi, R.; Perkins, W. Drug Dev. Res. 1995, 34, 35–38.
doi:10.1002/ddr.430340106

[33]. Novel EP1 receptor antagonists. Expert Opin. Ther. Patents 2004, 14, 435-438.

[34]. Breault, G.A. WO9700863A1, 1997.

[35]. Watanabe, K.; Kawamori, T.; Nakatsugi, S.; Ohta, T.; Ohuchida, S.; Yamamoto, H.; Maruyama, T.; Kondo, K.; Narumiya, S.; Sugimura, T.; Wakabayashi, K. Cancer Lett. 2000, 156, 57-61.
doi:10.1016/S0304-3835(00)00440-7

[36]. Ducharme, Y.; Blouin, M.; Carrière, M. C.; Chateauneuf, A.; Côte, B.; Denis, D.; Frenette, R.; Greig, G.; Kargman, S.; Lamontagne, S.; Martins, E.; Nantel, F.; O’Neill, G.; Sawyer, N.; Metters, K. M.; Friesen, R. W. Bioorg. Med. Chem. Lett. 2005, 15, 1155-1160.
doi:10.1016/j.bmcl.2004.12.005

[37]. Minami, T.; Nakano, H.; Kobayashi, T.; Sugimoto, Y.; Ushikubi, F.; Ichikawa, A.; Narumiya, S.; Ito, S. Br. J. Pharmacol. 2001, 133, 438-444.
doi:10.1038/sj.bjp.0704092
PMid:11375261    PMCid:1572799

[38]. Mebane, H.; Turnbach, M. E.; Randich, A. J. Pain 2003, 4, 392-399.
PMid:11160156    PMCid:199184

[39]. Stock, J. L.; Shinjo, K.; Burkhardt, J.; Roach, M.; Taniguchi, K.; Ishikawa, T.; Kim, H-S.; Flannery, P. J.; Coffman, T. M.; McNeish, J. D.; Audoly, L. P. J. Clin. Invest. 2001, 107, 325-331.
doi:10.1172/JCI6749

[40]. Omote, K.; Kawamata, T.; Nakayama, Y.; Kawamata, M.; Hazama, K.; Namiki, A. Anesth. Analg. 2001, 92, 233-238.
doi:10.1097/00000539-200101000-00045

[41]. Omote, K.; Yamamoto, H.; Kawamata, T.; Nakayama, Y.; Namiki, A. Anesth. Analg. 2002, 95, 1708-1712.
doi:10.1097/00000539-200212000-00044

[42]. Kawahara, H.; Sakamoto, T.; Takeda, S.; Onodera, H.; Imaki, J.; Ogawa, R. Anesth. Analg. 2001, 93, 1012-1017.
doi:10.1097/00000539-200110000-00043

[43]. Giblin, G. M. P.; Bit, R. A.; Brown, S. H.; Chaignot, H. M.; Chowdhury, A.; Chessell, I. P.; Clayton, N. M.; Coleman, T.; Hall, A.; Hammond, B.; Hurst, D. N.; Michel, A. D.; Naylor, A.; Novelli, R.; Scoccitti, T.; Spalding, D.; Tang, S. P.; Wilson, A. W.; Wilson, R. Bioorg. Med. Chem. Lett. 2007, 17, 385-389.
doi:10.1016/j.bmcl.2006.10.041

[44]. SYSTAT, Version 7.0; SPSS Inc., 444 North Michigan Avenue, Chicago, IL, 60611.

[45]. ChemDraw Ultra 6.0 and Chem3D Ultra, Cambridge Soft Corporation, Cambridge, USA. http://www.cambridgesoft.com

[46]. Dragon software (version 1.11-2001) by Todeschini R.; Consonni V. Milano, Italy. http://www.talete.mi.it/dragon.htm

[47]. Prabhakar, Y. S. QSAR Comb. Sci. 2003, 22, 583-595.
doi:10.1002/qsar.200330814

[48]. Wold, S. Technometrics 1978, 20, 397-405.
doi:10.2307/1267639

[49]. Kettaneh, N.; Berglund, A.; Wold, S. Comput. Stat. Data Anal. 2005, 48, 69-85.
doi:10.1016/j.csda.2003.11.027

[50]. Stahle, L.; Wold, S. Biomedical Research, Progress in Medicinal Chemistry, vol. 25, Elsevier Science Publishers, BV, 1998.

[51]. Sharma, B. K.; Pilania, P.; Singh, P.; Sharma, S.; Prabhakar, Y. S. Cent. Eur. J. Chem. 2009, 7, 909-922.
doi:10.2478/s11532-009-0073-4
PMid:18825552

[52]. Sharma, B. K.; Pilania, P.; Singh, P. J. Enz. Inhib. Med. Chem. 2009, 24, 607-615.
doi:10.1080/14756360802318878
PMid:19548781

[53]. Sharma, S.; Sharma, B. K.; Pilania, P.; Singh, P.; Prabhakar, Y. S. J. Enz. Inhib. Med. Chem. 2009, 24, 1024-1033.
doi:10.1080/14756360802608054
PMid:20373219

[54]. Sharma, B. K.; Pilania, P.; Singh, P.; Prabhakar, Y. S. SAR QSAR Environ. Res. 2010, 21, 169-185.
doi:10.1080/10629360903570545
PMid:19657719

[55]. Sharma, B. K.; Pilania, P.; Sarbhai, K.; Singh, P.; Prabhakar, Y. S. Mol. Divers. 2010, 14, 371-384.
doi:10.1007/s11030-009-9181-5

[56]. Akaike, H. Second international symposium on information theory, Akademiai Kiado, Budapest, 1973.

[57]. Akaike, H. IEEE Trans. Automat. Contr. 1974, AC-19, 716-723.
doi:10.1109/TAC.1974.1100705

[58]. Kubinyi, H. Quant. Struct.-Act. Relat. 1994, 13, 285-294.

[59]. Kubinyi, H. Quant. Struct.-Act. Relat. 1994, 13, 393-401.
PMid:9435904

[60]. Friedman, J. Technical report no. 102. Laboratory for computational statistics. Stanford University, Stanford, 1990.

[61]. So, S. -S.; Karplus, M. J. Med. Chem. 1997, 40, 4347-4359.
doi:10.1021/jm970487v

[62]. Prabhakar, Y. S.; Solomon, V. R.; Rawal, R. K.; Gupta, M. K.; Katti, S. B. QSAR Comb. Sci. 2004, 23, 234-244.
doi:10.1002/qsar.200330854

[63]. Gramatica, P. QSAR Comb. Sci. 2007, 26, 694-701.
doi:10.1002/qsar.200610151

[64]. Golbraikh, A.; Tropsha, A. J. Mol. Graph. Model. 2002, 20, 269-276.
doi:10.1016/S1093-3263(01)00123-1

Supporting Agencies

Most read articles by the same author(s)
TrendMD

Dimensions - Altmetric - scite_ - PlumX

Downloads and views

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...
License Terms

License Terms

by-nc

Copyright © 2024 by Authors. This work is published and licensed by Atlanta Publishing House LLC, Atlanta, GA, USA. The full terms of this license are available at https://www.eurjchem.com/index.php/eurjchem/terms and incorporate the Creative Commons Attribution-Non Commercial (CC BY NC) (International, v4.0) License (http://creativecommons.org/licenses/by-nc/4.0). By accessing the work, you hereby accept the Terms. This is an open access article distributed under the terms and conditions of the CC BY NC License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited without any further permission from Atlanta Publishing House LLC (European Journal of Chemistry). No use, distribution, or reproduction is permitted which does not comply with these terms. Permissions for commercial use of this work beyond the scope of the License (https://www.eurjchem.com/index.php/eurjchem/terms) are administered by Atlanta Publishing House LLC (European Journal of Chemistry).